Repertoire Immune Medicines
PrivateLast Round
Series B
Apr 13, 2021
Total Funding Raised
$214M
Momentum Score
25 /100
Company Overview
Repertoire Immune Medicines is a biotechnology company focused on harnessing the human immune system to develop targeted therapies for cancer, autoimmune disorders, infectious diseases, and other serious conditions through innovative T cell receptor (TCR)-antigen code technologies.
Sector
Healthcare & Life Sciences
Verticals
Drug Discovery, Biotechnology, Precision Medicine, Clinical Trials, Medical AI
Business Model
B2B
Customer Profile
Services & Consulting, Government Contracts
AI Layer
Application
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Repertoire Immune Medicines Comps
Public and private peers based on sector, stage, and business model.
Repertoire Immune Medicines Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series B | Apr 13, 2021 | ||||
| Grant | Jun 24, 2020 | ||||
| Early Funding | Mar 25, 2020 | ||||
| Series A | Nov 14, 2017 |
Repertoire Immune Medicines Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| SoftBank Investment Advisers | Series B |
| Public Sector Pension Investment Board | Series B |
| SoftBank Vision Fund 2 | Series B |
| Covid19 HPC Consortium | Grant |
| SoftBank Group | Series B |
| Invus Opportunities | Series B |
| Alaska Permanent Fund | Series B |
Market signals
Structured signals derived from secondary market and firmographic data.
- Apr 1, 2026
Announced strategic collaboration with Pfizer.
- Apr 1, 2026
$185M in upfront payments from four major pharma partners.
Repertoire Immune Medicines Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Frequently Asked Questions
Common questions about Repertoire Immune Medicines's valuation, stock price, and market status.
